Comparing melphalan doses before stem cell transplant for AML/MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different doses of a chemotherapy drug (melphalan) as part of the conditioning treatment before a stem cell transplant. The goal is to find which dose is safer and more effective for people with AML or MDS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) in first remission, OR myelodysplastic syndrome (MDS) with 5-20% blast cells in your bone marrow.
- You have a suitable stem cell donor (a matched sibling, a closely matched unrelated donor, or a half-matched family donor).
- You do not have an active infection that requires treatment right now.
- Your liver, kidneys, and heart are working normally or any problems are well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This study tests a less intense chemotherapy conditioning regimen before a stem cell transplant in people with myelodysplastic syndromes (MDS), a type of blood cancer where the bone marrow doesn't make enough healthy blood cells. The aim is to see if this approach is safer and still works well, potentially helping more people qualify for transplant.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
This trial compares two chemotherapy drugs, treosulfan and melphalan, used before a stem cell transplant in people with AML or MDS. The goal is to see which one works better with a special anti-rejection drug called PTCy.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
Hear when a new Survivorship trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.